Who are Evaxion A/S's main suppliers?

Evaxion A/S (EVAX) key suppliers include: PHARMAJET-INC, STATENS-SERUM-INSTITUT, BioNTech SE, BioNTech SE, Johnson & Johnson and 5 more. View the full supplier network at chainsifter.com/chain/EVAX.

Who are Evaxion A/S's major customers?

Evaxion A/S (EVAX) key customers include: BioNTech SE, BioNTech SE, Johnson & Johnson, Johnson & Johnson, Merck & Co., Inc. and 13 more. View the full customer network at chainsifter.com/chain/EVAX.

What sector is Evaxion A/S in?

Evaxion A/S (EVAX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Evaxion A/S Supplier List (EVAX): 10 Verified Suppliers

10Suppliers

18Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Evaxion A/S (EVAX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

30Total relationships

2Distinct source URLs

4High confidence

0.717Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Evaxion A/S Suppliers

Ticker	Name	Confidence	Evidence
PHARMAJET-INC	PHARMAJET-INC	90%	We have entered into license agreements, including with Statens Serum Institut (SSI) and PharmaJet, Inc., to obtain rights to intellectual property useful for pharmaceutical formulations and delivery…
STATENS-SERUM-INSTITUT	STATENS-SERUM-INSTITUT	90%	We have entered into license agreements, including with Statens Serum Institut (SSI) and PharmaJet, Inc., to obtain rights to intellectual property useful for pharmaceutical formulations and delivery…
BNTX	BioNTech SE	72%	ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. Prior to any out-licensing commercialization of EVX-01, we are not required to make…
BNTX	BioNTech SE	72%	Reciprocal relationship from BNTX graph: Reciprocal relationship from EVAX graph: ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. P…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from EVAX graph: ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. Pr…
JNJ	Johnson & Johnson	72%	ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. Prior to any out-licensing commercialization of EVX-01, we are not required to make…
MRK	Merck & Co., Inc.	72%	bstantial amounts to continue the development of our GD-T cell-based therapeutic candidates, including for future clinical trials. In the event of unstable markets and unfavorable market conditions, …
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from EVAX graph: bstantial amounts to continue the development of our GD-T cell-based therapeutic candidates, including for future clin…
SNYNF	Sanofi	72%	ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. Prior to any out-licensing commercialization of EVX-01, we are not required to make…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVAX graph: ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. …

Evaxion A/S Customers

Ticker	Name	Confidence	Evidence
BNTX	BioNTech SE	72%	drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholder…
BNTX	BioNTech SE	72%	Reciprocal relationship from BNTX graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from BNTX g…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from EVAX graph: drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In …
JNJ	Johnson & Johnson	72%	drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholder…
MRK	Merck & Co., Inc.	72%	bstantial amounts to continue the development of our GD-T cell-based therapeutic candidates, including for future clinical trials. In the event of unstable markets and unfavorable market conditions, …
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from MRK grap…
NVO	Novo Nordisk A/S	72%	Reciprocal relationship from NVO graph: Reciprocal relationship from EVAX graph: of operations, financial position and overall trends. In addition, regardless of the outcome, litigation can be costly…
NVO	Novo Nordisk A/S	72%	of operations, financial position and overall trends. In addition, regardless of the outcome, litigation can be costly, time-consuming, and disruptive to our operations. Any claims or litigation, eve…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVAX graph: drugs, has become intense. As a r…
SNYNF	Sanofi	72%	drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholder…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	. Under the Delaware General Corporation Law, a corporation’s certificate of incorporation may be amended only if adopted and declared advisable by the board of directors and approved by a majority o…
EMERGING-GROWTH-COMPANY	EMERGING-GROWTH-COMPANY	62%	707 ) ( 7,707 ) Other comprehensive income — — — 365 — 365 Share-based compensation 9 — — 342 — — 342 Issuance of shares for cash 19 5,275 19,794 — — — 25,069 Non-cash effect from issue of investor w…
GLOBAL-GROWTH-HOLDING-LIMITED	GLOBAL-GROWTH-HOLDING-LIMITED	62%	ains of $5.5 million from remeasurement of derivative liability related to the 2024 Investor Warrants and 2023 SPA Warrants and foreign currency gains of $0.5 million, a gain from changes in fair val…
LINCOLN-PARK-CAPITAL-FUND-LLC	LINCOLN-PARK-CAPITAL-FUND-LLC	62%	ains of $5.5 million from remeasurement of derivative liability related to the 2024 Investor Warrants and 2023 SPA Warrants and foreign currency gains of $0.5 million, a gain from changes in fair val…
PASSIVE-FOREIGN-INVESTMENT-COMPANY	PASSIVE-FOREIGN-INVESTMENT-COMPANY	62%	ormation only and does not purport to constitute tax or legal advice. It is specifically noted that the summary does not address all possible tax consequences relating to an investment in the ADSs. T…
ROCHE-GROUP	ROCHE-GROUP	62%	of operations, financial position and overall trends. In addition, regardless of the outcome, litigation can be costly, time-consuming, and disruptive to our operations. Any claims or litigation, eve…
SUBSIDIARY-SHARES-GROUP	SUBSIDIARY-SHARES-GROUP	62%	ormation only and does not purport to constitute tax or legal advice. It is specifically noted that the summary does not address all possible tax consequences relating to an investment in the ADSs. T…
TRILLIUM-THERAPEUTICS-INC	TRILLIUM-THERAPEUTICS-INC	62%	of operations, financial position and overall trends. In addition, regardless of the outcome, litigation can be costly, time-consuming, and disruptive to our operations. Any claims or litigation, eve…

Evaxion A/S Debt Obligations

Instrument	Description	Confidence	Evidence
EVAX-DEBT	Debt stack $7.5M	90%	Market cache reports total debt of $7.5M.

Evaxion A/S Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Evaxion A/S.

Evaxion A/S Ownership

Holder	Name	Confidence	Evidence
EVAX-OWNER-IKARIAN-CAPITAL-LLC	Ikarian Capital, LLC	90%	13F overlay lists Ikarian Capital, LLC as top holder; 16 tracked holders.

Evaxion A/S Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BMY	Bristol-Myers Squibb Company	100.00	2
HIMS	Hims & Hers Health, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
BNTX	BioNTech SE	100.00	1	['customer', 'supplier']
ENLV	Enlivex Ltd.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2
CANF	Can-Fite BioPharma Ltd.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
TBPH	Theravance Biopharma, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
ZTS	Zoetis Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
IBRX	ImmunityBio, Inc.	100.00	2

Evaxion A/S Supply Chain